With increasing choice of glucose lowering drugs for type 2 diabetes it is now possible to select an agent based on the potential of the agent to confer end-organ protection.  The SGLT2 inhibitors appear not only to have a mode of action which is located within the kidney but also based on a number of studies to confer renoprotection, as assessed by a reduction in albuminuria and a stablisation in the decline in GFR.  These effects have been seen with various SGLT2 inhibitors but the most definitive results have been obtained as part of a secondary analysis of the EMPA-Reg study